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(SUSPEND), a multicentre, placebo-controlled,
randomized trial of a calcium-channel blocker
(nifedipine) and an α-blocker (tamsulosin): study
protocol for a randomized controlled trial
Sam McClinton1,2*, Kathryn Starr2,3, Ruth Thomas3, Graeme McLennan3, Gladys McPherson3, Alison McDonald3,
Thomas Lam1,2, James N’Dow1,2, Mary Kilonzo4, Robert Pickard5, Ken Anson6, Jennifer Burr7
for the SUSPEND Study GroupAbstract
Background: Urinary stone disease is common, with an estimated prevalence among the general population of 2%
to 3%. Ureteric stones can cause severe pain and have a significant impact on quality of life, accounting for over
15,000 hospital admissions in England annually. Uncomplicated cases of smaller stones in the lower ureter are
traditionally treated expectantly. Those who fail standard care or develop complications undergo active treatment,
such as extracorporeal shock wave lithotripsy or ureteroscopy with stone retrieval. Such interventions are expensive,
require urological expertise and carry a risk of complications.
Growing understanding of ureteric function and pathophysiology has led to the hypothesis that drugs causing
relaxation of ureteric smooth muscle, such as the selective α-blocker tamsulosin and the calcium-channel blocker
nifedipine, can enhance the spontaneous passage of ureteric stones. The use of drugs in augmenting stone
passage, reducing the morbidity and costs associated with ureteric stone disease, is promising. However, the
majority of clinical trials conducted to date have been small, poor to moderate quality and lacking in
comprehensive economic evaluation.
This trial aims to determine the clinical and cost-effectiveness of tamsulosin and nifedipine in the management of
symptomatic urinary stones.
Methods/design: The SUSPEND (Spontaneous Urinary Stone Passage ENabled by Drugs) trial is a multicentre,
double-blind, randomized controlled trial evaluating two medical expulsive therapy strategies (nifedipine or tamsulosin)
versus placebo.
Patients aged 18 to 65 with a ureteric stone confirmed by non-contrast computed tomography of the kidney, ureter
and bladder will be randomized to receive nifedipine, tamsulosin or placebo (400 participants per arm) for a maximum
of 28 days. The primary clinical outcome is spontaneous passage of ureteric stones at 4 weeks (defined as no further
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intervention required to facilitate stone passage). The primary economic outcome is a reduction in the incremental cost
per quality-adjusted life years, determined at 12 weeks. The analysis will be based on all participants as randomized
(intention to treat). The trial has 90% power with a type I error rate of 5% to detect a 10% increase in primary outcome
between the tamsulosin and nifedipine treatment groups.
Trial registration: ISRCTN69423238; EudraCT number: 2010-019469-26
Keywords: medical expulsive therapy, nifedipine, tamsulosin, ureteric stoneBackground
Urinary stone disease is very common, with an estimated
prevalence among the general population of 2% to 3%
and an estimated lifetime risk of 1 in 8 for white males
[1] and 5% to 6% for white females [2], with men form-
ing stones three times as often as women. Urinary stones
often recur and the lifetime recurrence rate is approxi-
mately 50% [3]. The interval between recurrences is
variable, with approximately 10% within 1 year, 35% within
5 years and 50% within 10 years [2]. The increased in-
cidence of urinary stones in the industrialized world is
associated with improved standards of living (mainly
owing to the high dietary intake of proteins and minerals)
and there is also an association with ethnicity and region
of residence [4]. All urinary tract stones, and ureteric
stones in particular, have a significant impact on patients’
quality of life. They are a common cause of emergency
hospital admission due to severe pain with over 15,000
hospital admissions in England annually [5] using over
21,500 bed days. The pain leads to a requirement for anal-
gesia, time off work and, often, repeated hospital admis-
sions for therapeutic interventions.
A clinical guideline on the management of ureteric
stones by the European Association of Urology and the
American Urological Association [6] estimates that 68%
of stones ≤5 mm and 47% of stones 5 to 10 mm in size
can be expected to pass spontaneously and concluded
that the majority of these stones pass within 4 to 6 weeks
of presentation. Stones in the distal ureter pass more
readily than stones located more proximally. The majority
of the studies included in the guideline meta-analysis
assessed stones in the distal (lower) ureter only. Conse-
quently, patients with favourable features and with
smaller stones in the lower ureter are traditionally
treated expectantly. Those who fail standard supportive
care (which involves analgesia, anti-emetics if nauseated,
and intravenous fluids if there is associated vomiting), or
who subsequently develop complications, undergo active
treatment, such as extracorporeal shock wave lithotripsy,
ureteric stenting, ureteroscopy with stone retrieval or
in-situ lithotripsy, or percutaneous nephrostomy insertion.
However, such interventions are expensive, require uro-
logical expertise and carry a risk of complications. For in-
stance, extracorporeal shock wave lithotripsy is associatedwith up to 5% risk of sepsis and up to 8% risk of im-
paction of stone fragments causing urinary obstruction
(‘Steinstrasse’), whilst ureteroscopy is associated with up to
4% risk of sepsis and up to 6% risk of ureteric injury [6].
In recent years, a growing understanding of ureteric
function and pathophysiology has led to the hypothesis
that drugs that cause relaxation of ureteric smooth muscle
can enhance the spontaneous passage of ureteric stones
[7-9]. The selective α-blocker, tamsulosin has specificity
for α-1A and α-1D receptor subtypes [10,11], whilst other
α-blockers variably block all α-1 receptor subtypes in a
non-specific manner [12-14]. Similarly, calcium-channel
blockers, such as nifedipine, inhibit ureteric smooth muscle
contraction [15,16]. The use of both classes of drugs in aug-
menting the passage of ureteric stones has been termed
medical expulsive therapy (MET) and this is proposed
as a way to enhance stone passage and avoid the need
for further intervention.
Two recent meta-analyses have reported the potential
role of α-blockers and calcium-channel blockers in MET.
Hollingsworth and co-workers [17] included nine random-
ized controlled trials, which included 693 subjects, although
all but one trial had serious methodological flaws. Studied
interventions included the calcium-channel blocker nifedi-
pine and several different α-blockers whilst the comparative
control arms included placebo, other vasodilators, anti-
spasmolytics, anticholinergic therapy and corticosteroids.
Overall spontaneous stone passage occurred in 47% of the
control group whilst patients given MET with either drug
were 65% more likely to pass the stone, with an absolute
risk reduction of 31%. Three studies reported a head-to-
head comparison between nifedipine and α-blockers. Two
of these studies did not report any statistically significant
difference in stone passage rates between the two drugs,
whilst one study found the α-blocker to be superior to ni-
fedipine, with a relative risk reduction of 26%.
In a more recent systematic review and meta-analysis,
Singh and colleagues [18] included 22 studies; of which
13 assessed α-blockers, 6 assessed nifedipine, and 3
assessed both drugs against control. In the pooled ana-
lysis of 16 studies using α-blockers (n = 1,235), those re-
ceiving active treatment were 59% more likely to pass
the stone, with a baseline stone passage rate of 50% in
the control group. The incidence of mild adverse effects
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(nine studies, n = 686) showed that active treatment gave a
50% increased likelihood of stone passage, with an abso-
lute risk reduction of 26%. The incidence of mild adverse
effects was 15%. Both drugs significantly shortened, by be-
tween 2 and 6 days, the average time to stone expulsion
[18]. However, the overall quality of the trials was poor.
In both meta-analyses, the majority of studies involved
stones <10 mm located in the lower (distal) ureter. These
two reviews both concluded that a large, high-quality
randomized controlled trial is required to confirm
their findings, suggesting that MET with either drug
class can enhance spontaneous stone passage rate. In
addition, several studies have previously reported that
MET can significantly reduce the pain burden among
patients in terms of reducing the frequency of pain epi-
sodes, pain severity and analgesic requirements.
However, more recent results provided by Bensalah
and co-workers [19] appear to challenge the notion that
α-blockers enhance spontaneous ureteric stone passage.
The study, recently presented as an abstract, was a
prospective, multicentre, randomized, double-blind,
placebo-controlled trial, which evaluated the efficacy
of tamsulosin versus placebo in patients with ureteric
colic caused by distal ureteric stones. A total of 129 pa-
tients were treated for 42 days or until stone expulsion.
At 42 days, there was no significant difference between
the spontaneous expulsion rates between placebo (70.5%)
and tamsulosin (77.0%; P = 0.41), nor in the mean stone
passage times (10.1 and 9.6 days, respectively). Neverthe-
less, the overall mean stone diameter was 3.1 mm, which
is smaller than all of the earlier studies included in the
meta-analyses by Hollingsworth [17] and Singh [18]. The
spontaneous stone passage rate in the placebo arm was
high (70.5%) in comparison with other studies included in
the two meta-analyses.
There is limited evidence on the cost-effectiveness of
MET; an indirect cost-benefit analysis based on cost data
from the USA and four European countries suggested
that the use of tamsulosin could potentially result in a
cost saving of US$ 1,132 per patient episode over con-
ventional ‘watchful waiting’ [20].
In summary, the role of MET in reducing the morbidity
and economic costs associated with ureteric stone disease
is promising. The majority of clinical trials conducted to
date have been small and of poor to moderate quality in
terms of trial methodology or design. Furthermore, they
have lacked a comprehensive economic evaluation. There is
thus an urgent need for a definitive randomized controlled
trial, such as that described in this protocol to inform the
clinical management of patients with ureteric stone disease.
For the purposes of this randomized controlled trial, we
have chosen to compare tamsulosin versus nifedipine. The
weight of available evidence supports the use of tamsulosinas the α-blocker of choice in MET for ureteric stones. In
the two previous reviews [17,18], tamsulosin was the agent
of choice in 13 out of 16 randomized controlled trials. As
discussed earlier, there also appears to be a theoretical ad-
vantage in using tamsulosin, owing to its specificity for the
α-1A and α-1D adrenergic receptor subtypes. Similarly, the
reviews also suggest that nifedipine should be the calcium-
channel blocker of choice. The eight randomized controlled
trials identified in Singh [17] and Hollingsworth [18] that
examined the efficacy of calcium-channel blockers all used
nifedipine. Nifedipine is also in widespread use in the UK’s
National Health Service (NHS) for other indications.
The main anticipated risk to participants is that they
suffer an adverse reaction to the trial medication.
Treatment with α-blocker or nifedipine is associated
with a small risk of adverse effects. In the report by
Singh and colleagues [18], the incidence of mild ad-
verse effects was 4% with α-blocker and 15% with ni-
fedipine. However, both trial drugs are in common use
for different indications, and the undesirable effects
(such as postural hypotension and tachycardia) are well
recognized. Patients with a contraindication to either
drug will not be included in the trial. The off-label use of
tamsulosin in women is well documented in the literature
and there have not been any reports of any specific adverse
reactions to treatment in female participants. However, the
risks of tamsulosin use during pregnancy are unknown and
nifedipine is contraindicated during pregnancy. Two suit-
able ‘highly effective’ forms of contraception must be used
by women of childbearing potential entering the trial.
The aim of this trial is to determine the clinical effective-
ness and cost-effectiveness of the use of tamsulosin and ni-
fedipine in the management of symptomatic urinary stones.
The potential benefits to participants are that the pain and
discomfort caused by their ureteric stones will be relieved
sooner and the avoidance of additional treatment (such as
ureteroscopy or extracorporeal shock wave lithotripsy) will
be reduced by 25% to 45%.
In the context of all trial groups receiving standard sup-
portive care, two pragmatic comparisons will be made in
evaluating MET for the facilitation of ureteric stone passage:
 Medical expulsive therapy (an α-blocker (tamsulosin) or
a calcium-channel blocker (nifedipine)) versus placebo.
 An α-blocker (tamsulosin) versus a calcium-channel
blocker (nifedipine).
The hypotheses being tested are:
1. The use of MET will result in an absolute increase
in the spontaneous stone passage rate of at least 25%
compared with placebo.
2. The use of an α-blocker (tamsulosin) will result in
an absolute increase of 10% in the spontaneous
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blocker (nifedipine).
Methods/design
This is a multicentre, double-blind, placebo-controlled,
randomized trial evaluating two MET treatments
(nifedipine or tamsulosin) versus placebo. The trial will be
conducted in secondary care units with a high volume of
admissions with ureteric stones across the UK. Figure 1
summarizes the trial design.
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 Women who have a known or suspected pregnancy
(confirmed by a pregnancy test).
 Women who are breastfeeding.
 Asymptomatic incidentally found ureteric stone.
 Stone not previously confirmed by CTKUB.
 Stone with any one dimension >10 mm.
 Kidney stone without the presence of ureteric
stone.
 Multiple (that is ≥ 2) stones within ureter.
 Bilateral ureteric stones.
 Stone in a ureter draining a solitary kidney
(either anatomically or functionally).
 Patients with abnormal renal tract anatomy (such as
a duplex system, horseshoe kidney or ileal conduit).
 Presence of urinary sepsis.
 Chronic kidney disease stage 4 or stage 5 (estimated
glomerular filtration rate < 30 ml/min).
 Patients currently taking an α-blocker.
 Patients currently taking a calcium-channel blocker.
 Patients currently taking PDE5 inhibitors.
 Contraindication or allergy to tamsulosin or nifedipine.
 Patients who are unable to understand or complete
trial documentation.
Women who are eligible to take part in the trial and
are of childbearing potential (that is, are not postmeno-
pausal (defined as 12 months with no menses without
an alternative medical cause) or permanently sterilized)
will be advised to use two forms of highly effective birth
control (that is, results in a less than 1% per year failure
rate) and continue use until at least 28 days after the last
dose of trial medication. Acceptable forms of contracep-
tion include:
 Established use of oral, transdermal, injected or
implanted hormonal methods of contraception.
 Placement of an intrauterine device or intrauterine
system.
 Barrier methods of contraception: condom or
occlusive cap (diaphragm or cervical or vault caps)
in combination with a spermicidal foam, gel, film,
cream or suppository.
 The woman’s sole male partner is sterile (with the
appropriate post-vasectomy documentation of the
absence of sperm in the ejaculate) before her
participation in the trial.
 True abstinence, when this is in line with the
preferred and usual lifestyle of the subject. Periodic
abstinence (for example, calendar, ovulation,
symptothermal, postovulation methods) and
withdrawal are not acceptable methods of
contraception for trial purposes.Trial interventions
Two active treatments will be investigated:
1. Tamsulosin, 0.4 mg/day up to a maximum of 28 days.
2. Nifedipine, 30 mg/day up to a maximum of 28 days.
Identification and enrolment of potential participants
As standard practice, clinicians will assess patients present-
ing with suspected ureteric calculi. A log will be taken of all
patients assessed, in order to document the reasons for
non-inclusion in the study (for example, reason they were
ineligible, declined to participate) to inform the CONSORT
diagram. Following adequate pain relief and confirmation
of ureteric calculi by CTKUB, eligible patients (according
to the inclusion and exclusion criteria) will be provided
with a patient information leaflet. The information leaflet
will be given to each potential participant to explain the
benefits and known drawbacks of all aspects of this trial. It
shall specifically explain that the trial will investigate the ef-
fect of two different drugs against a placebo, and explain
the likelihood of participants receiving each of the three
trial treatments. A member of the local research team will
identify whether the patient is interested in the trial and will
ensure that any questions the patients have are answered
appropriately. The patients will be given as long as they re-
quire, prior to discharge, to make a decision about whether
or not to participate. Signed informed consent forms will
be obtained from the participants in all centres, by an indi-
vidual who is appropriately trained. On providing consent,
the patient will be asked to complete a baseline question-
naire and will then be randomized to one of the three treat-
ment groups. The participant’s permission will be sought to
inform their general practitioner (GP) that they are taking
part in this trial.
Randomization and allocation
Eligible and consenting participants will be randomized to
one of the two intervention groups or the placebo group
on a 1:1:1 basis using the proven telephone interactive
voice response randomization application hosted by
the Centre for Healthcare Randomized Trials (CHaRT)
and the Health Services Research Unit in Aberdeen.
The randomization algorithm will use centre, stone
size and stone location as minimization covariates. Upon
randomization, the participant will be allocated a unique
participant study number and assigned a numbered partici-
pant pack containing over-encapsulated trial medication to
ensure that the participant, investigator and trial personnel
remain blind to treatment.
Code break or emergency unblinding
Participants will be given a patient card, which will have
the study title, investigational medicinal product details,
participant ID and out-of-hours contact details, in case
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only be broken for valid medical or safety reasons, for
example, in the case of a severe adverse event, where it is
necessary for the principal investigator or treating health-
care professional to know which treatment the participant
is receiving, to determine emergency treatment. Where
possible, the members of the research team should remain
blinded, subject always to clinical need.
In the event of a clinical emergency requiring unblinding,
the first point of contact is the local research team where
the participant was recruited to the trial. The participant
will be given a card to carry with details of a contact
telephone number at the site (for example, the number for
the on-call urologist), to be used in the event that unblind-
ing is necessary. Contact information will also be available
in the participant’s hospital notes.
A member of the research team or a member of staff
at the local recruiting site will telephone the CHaRT
randomization service at the number provided using
the trial centre ID and the participant study number
(the trial ID number will be available from the patient
card or the participant’s hospital notes). The name and
position of the person making the call will be recorded.
In the unlikely event of randomization service failure,
the on-call pharmacist at Aberdeen Royal Infirmary
will be contacted and the same procedure followed.
Following any unblinding via the telephone randomization
service, automatic emails will be sent to the chief investiga-
tor, trial manager and members of the CHaRT Management
team. Similarly, the on-call pharmacist will email the same
list of people to inform them of any unblinding. These
emails will not contain the treatment code and the trial
team will remain blinded as far as is practicable.
The chief investigator will then ascertain why unblind-
ing has taken place. If the participant was unblinded
because of a serious adverse event, an SAE form will be
completed and will be reported as stipulated below
(Safety – Procedure for recording adverse events).
Trial procedures
Participants will complete three questionnaires. The base-
line questionnaire will be completed in hospital after entry
into the trial (but before participants receive their study
medication). Two further postal questionnaires, one at 4
and one at 12 weeks post randomization, will be sent from
the co-ordinating office (CHaRT, Aberdeen). In addition,
participants may be reviewed in clinic at approximately
4 weeks after randomization (as is common in routine
NHS care). In the event that the participant does not
return the questionnaire, a reminder letter will be sent
out approximately 2 weeks later.
Three case report forms will be completed by the re-
search team at the recruiting site, one at baseline and one
at the follow-up visit (in the case of non-attendance, thisform will completed from the participant’s notes). If partici-
pants indicate on the 12-week questionnaire that they have
had further interventions since their 4-week questionnaire,
a further case report form will be completed from the
participant’s notes. Additionally if the participant fails to
return the 12-week questionnaire a 12-week CRF will be
completed from their medical records.
The complete trial processes are shown in Figure 2.
Subject withdrawal
Participants will remain on the trial unless they chose to
withdraw consent or the principle investigator, chief investi-
gator or trial manager feels it is no longer appropriate for
the participant to continue (for example, the participant
becomes unable to complete the trial documentation).
Once the participant has been withdrawn from the trial,
participant questionnaires will not be collected; how-
ever, permission will be sought for the research team to
continue to collect outcome data from the participant’s
hospital notes (using the case report forms).
In the event that participants are withdrawn from the
study medication for any reason (for example, a serious
adverse reaction or event occurs), they will still continue
in the trial and will be asked to complete the trial
documents.
Trial medications
Investigational medicinal products
Tamsulosin hydrochloride (Petyme) will be sourced by
Tayside Pharmaceuticals from Teva UK in the form of
400 μg modified release capsules.
Nifedipine (Coracten) will be sourced by Tayside
Pharmaceuticals from UCB Pharma in the form of
30 mg sustained release capsules.
The placebo will be manufactured by Tayside
Pharmaceuticals.
The medicinal products will be over-encapsulated to
maintain the blinding of the trial. Trial medication will
be presented as capsules in amber glass containers with
a childproof closure and labelled according to Annex 13
of Volume 4 of The Rule Governing Medicinal Products
in the EU: Good Manufacturing Practices [21].
The medicinal products and the placebo will be over-
encapsulated, packaged and labelled by Tayside Pharmaceu-
ticals according to good manufacturing practice.
Dosing regimen
Participants will take one capsule of the trial medication
per day until stone passage occurs or for a maximum of
28 days.
Drug accountability
Blinded treatment packs will be stored by the local
pharmacy according to manufacturer’s instructions
Patient presents with symptomatic 
ureteric calculi 
Clinical staff assess patient Not eligible
Patient Information Sheet provided Patients not wishing to 
entering trial 
Patient first presents in 
hospital
Informed consent obtained 
Complete Baseline
Case Report Form
Provide participant with 
Baseline questionnaire
RANDOMIZED
Input Baseline Information into 
website
GP letter generated by the trial office
Four weeks post 
randomized (participants 
follow-up visit in hospital 
and postal questionnaire)
Twelve week post 
randomized (postal 
questionnaire follow-up)
Participant provided with postal 
questionnaire four weeks post 
randomization
Input into website
Research nurse completes four week
Case Report Form
Need for additional treatment/surgery 
obtained from patients notes/records 
Input into website
Provide participant with 12 weeks 
post randomizationquestionnaire 
Input into website
Research team complete 12 week
Case Report Form
Need for additional treatment/surgery 
obtained from patients notes/records 
Input into website
Figure 2 SUSPEND trial processes.
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records will be kept by the pharmacy.
Subject compliance
Upon randomization, each participant will be assigned a
unique participant numbered pack of blinded medication.
Participants will be instructed to store the medication ac-
cording to the manufacturer’s instructions. Participants
will be asked to record whether they completed the full
course of treatment in the 4-week questionnaire. Unused
medication or empty packaging should be returned by
the participant at the 4-week follow-up visit and
returned to the pharmacy. Participants who do not at-
tend the 4-week visit will be instructed to destroy the
medication. Participants will also be treated with the
usual standard of care at the treating establishment, in-
cluding prescribed analgesia.Concomitant medications
Patients currently taking rifampicin or digoxin are excluded
from the trial. Potential interactions are taken from the
summary of product characteristics for each product; the
participant’s GP will also receive this information.
Outcome measures
The trial has a primary clinical and a primary economic
outcome, reflecting the multidimensional nature of the
possible effects the intervention may have.
Primary
 Clinical: the primary outcome is spontaneous
passage of ureteric stones at 4 weeks (defined as
no further intervention required to facilitate
stone passage).
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quality-adjusted life years (QALYs) gained at
12 weeks. The calculation of QALYs will be based
on the participants’ responses to the EQ5D.
Secondary
 Patient-reported: a reduction in the severity of pain
as measured by a numeric rating scale [22,23].
Generic health profile will be measured by the SF 36
and the use of analgesia.
 Clinical: time to passage of stone; further
interventions received at 12 weeks.
 Safety: participant-reported discontinuation of trial
medications.
 Economic: NHS primary and secondary care use
and costs up to three months, incremental cost per
surgical interventions averted; modelled
incremental cost per QALY beyond the 12-week
trial follow-up.
Timing and measurement of outcome assessment
Outcomes will be assessed at 4 weeks and 12 weeks post
randomization, as shown in Table 1.
Safety
Timing and recording of safety parameters
Information regarding participant discontinuation of
medication due to adverse events will be collected at
4 weeks in the participant questionnaire.
Procedures for recording and reporting adverse events
Adverse events that will not be reported Non-serious
events will not be collected or reported. Planned hospital
visits for conditions other than those associated with the
ureteric stone will not be collected or reported. HospitalTable 1 Source and timing of measures
Outcome measures Source
Need for additional intervention Case report form
Additional interventions received Participant questionnaire a
Pain (numeric rating scale) Participant questionnaire
Health profile and status (SF36, EQ5D) Participant questionnaire
Use of analgesics Participant questionnaire
Adverse events Participant questionnaire
Time to passage of stone Participant questionnaire a
NHS primary and secondary healthcare use Participant questionnaire a
Participant out of pocket costs Participant questionnaire
EQ5D, European Quality of Life, 5 Dimensions; SF36, Short Form (36) Health Survey.admissions (planned or unplanned) associated with the
treatment of the ureteric stone diagnosed at the time of
entry to the trial are expected. These will be recorded as
an outcome measure, but will not be recorded or reported
as serious adverse events.
Procedure for adverse event recording in this trial
All adverse events will be assessed in respect of sever-
ity (serious or not), relationship to trial medication
(suspected or not suspected), whether expected or un-
expected, duration and, therefore, whether constituting a
serious adverse event, by the local principle investigator or
chief investigator, or their deputies.
Participants will be advised to contact their GPs should
they experience an adverse event between the period
following treatment and the 12-week follow-up question-
naire. This is current clinical practice for participants re-
ceiving tamsulosin or nifedipine within the NHS. When
notified of trial participation, GPs will be asked to notify
the trial office of any serious adverse reactions or events
(for example, unexpected admission to hospital) in a
timely manner. This will provide a robust system for
the notification of any serious adverse reactions or serious
adverse events (both expected and unexpected) occurring
outside the trial visit.
1. Non-serious adverse events will not be collected.
Participants will be asked whether they discontinued
the study medication due to adverse reactions in the
4-week questionnaire.
2. All confirmed serious adverse events are to be
notified to the co-sponsors and chief investigator as
soon as the investigator or trial office (via a GP)
becomes aware, either orally or in writing, of the
event, and this should be followed by a written
report on the event.Timing
Recruitment Post randomization
4 weeks 12 weeks
× ×
nd case report form × ×
× ×
× × ×
×
× ×
nd case report form × ×
nd case report form ×
×
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Fatal or life-threatening suspected unexpected serious
adverse reactions (SUSARs)
The chief investigator (or his designee) or co-sponsor will
forward reports on fatal or life-threatening suspected unex-
pected serious adverse reactions (SUSARs) (that is, serious
unexpected adverse events where a causal link between the
drug and the event is suspected) to the Medicines and
Healthcare Regulatory Authority (MHRA) and the research
ethics committee within 7 days of their first knowledge
of the minimum criteria using the relevant proforma.
A copy will also be sent to the co-sponsor, the manufac-
turer and the data-monitoring committee. Follow-up in-
formation will be forwarded to the MHRA and ethics
committee within 8 days.Non-fatal and non-life-threatening SUSARs
The chief investigator (or designee) or co-sponsor will
forward reports on non-fatal and non-life-threatening
SUSARs to the MHRA and the research ethics committee
within 15 days of their first knowledge of the minimum
criteria using the relevant proforma. A copy will be sent to
the co-sponsors, the manufacturer and the data-monitoring
committee. Follow-up information will be forwarded to the
MHRA and ethics committee within 8 days.All other serious adverse reactions
The trial office, with the assistance of the chief investigator,
will prepare a summary of all serious adverse reactions
every six months. These will be distributed to the par-
ticipating investigators, co-sponsors, manufacturer, trial
steering committee and data-monitoring committee.
In addition, all suspected serious adverse reactions will
be collated annually and submitted to theresearch ethics
committee and the MHRA, in accordance with the
guidance on annual safety reporting.
The data-monitoring committee will regularly assess the
safety data collected for the trial and will have the ability
to advise that the trial is temporarily or permanently halted
based on safety concerns, according to the criteria defined
in their charter.Pregnancies
Pregnancy is not regarded as a serious adverse event, but
will be recorded and reported. Pregnancy will be prevented
as far as is practicable, but in the event a woman does be-
come pregnant on the trial, she will be followed throughout
her pregnancy and any serious adverse events at delivery
will be recorded and reported. If necessary, the develop-
ment of the newborn will be monitored for an appropriate
period after delivery.Sample size
The combined data from the two recent meta-analyses
[17,18] suggest a relative risk of approximately 1.50, com-
paring MET (either α-blocker or calcium-channel blocker)
against ‘standard care’ on the primary outcome. These
reviews indicate a spontaneous stone passage rate of
approximately 50% in control groups in the included
randomized controlled trials. Only three of the included
randomized controlled trials directly compared a calcium-
channel blocker with an α-blocker, and these suggested that
α-blockers are likely to be superior to calcium-channel
blockers. Combining information from Singh [18] and
Hollingsworth [17], stone passage rates for the α-blocker
and calcium-channel blocker groups were approximately
85% and 75%, respectively. The most conservative sample
size is required to detect superiority between the two
active treatments and to this end will power the trial.
To detect an increase of 10% in the primary outcome
(spontaneous stone passage) from 75% in the calcium-
channel blocker group to 85% in the α-blocker group,
with type I error rate of 5% and 90% power, requires
354 per group; adjusting for 10% loss to follow-up inflates
this to 400 per group. Since all treatment comparisons are
pre-specified, no adjustment for multiplicity has been
made [24]. Recruiting 1,200 participants (randomizing 400
to each of the three treatment groups; α-blocker, calcium-
channel blocker and placebo) would provide sufficient
power (>90%) for all other comparisons of interest.
Procedures to minimize bias
The trial will be conducted double blind, that is, the par-
ticipant, investigator and personnel involved in the trial
(with the exception of the data-monitoring committee
members and allocated statistician) will be unaware of
each individual’s treatment allocation.
Statistical analysis
Two comparisons will be considered for the primary
trial analysis:
1. Medical expulsive therapy (an α-blocker (tamsulosin)
or a calcium-channel blocker (nifedipine)) versus
placebo.
2. An α-blocker (tamsulosin) versus a calcium-channel
blocker (nifedipine).
Treatment groups will be described at baseline and
follow-up using means (with standard deviations), medians
(with interquartile ranges) and numbers (with percentages)
where relevant. Primary and secondary outcomes will be
compared using generalized linear models, with adjustment
for participant baseline and minimization covariates: trial
centre; stone size (≤5 mm or >5 mm to 10 mm); and
location in ureter (upper, middle or lower). All estimates
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intervals. Statistical significance will be at the 5% level. Pri-
mary analyses will be by allocated group (intention to treat).
Subgroup analyses (appropriately analyzed by testing
treatment by subgroup interaction) will explore the pos-
sible effect modification of a number of factors: stone size
(≤5 mm or >5 mm to 10 mm); location in ureter (upper,
middle or lower); and sex; all using stricter levels of statis-
tical significance (P < 0.01, 99% confidence intervals).
All statistical analyses and reporting will follow a care-
fully documented statistical analysis plan. The trial steer-
ing committee and an independent data-monitoring
committee will be asked to review and comment on the
statistical analysis plan prior to any analysis and the plan
will be finalized prior to any unblinding of the data. A
single main analysis will be performed at the end of the
trial when all follow-up has been completed. The data-
monitoring committee will meet once 300, 600 and 900
participants have been randomized, to discuss interim
analysis reports and the criteria for stopping the trial. The
statistical analysis plan and data-monitoring committee
charter will document the agreed timings and strategy.
Economic evaluation
Economic evaluation will be an integral part of the trial.
Resource use and costs will be estimated for each par-
ticipant. Resource data collected will include the costs of
the intervention drugs and simultaneous and consequent
use of primary and secondary NHS services by partici-
pants. Personal costs, such as purchase of medications,
time and travel will also be estimated. The perspective of
the trial will be societal as it will include costs to both
the NHS and the participants.
Collection of data
At recruitment, data will be collected on the intervention
that the participants receive. Participants will be asked to
provide information about their use of analgesics at 4 and
12 weeks post randomization, and about their primary and
secondary healthcare service use at 12 weeks. They will also
be asked for information about the time they spent travel-
ling to primary and secondary health service providers and
resources they might have used, such as mode of transport.
Participant costs
Participant costs will comprise self-purchased healthcare
and travel and time costs for accessing NHS care. Self-
purchased healthcare will include such items as prescrip-
tion costs and over-the-counter medications. Information
about these will be collected using a healthcare utilization
questionnaire at 12 weeks. Participants will be asked for
information on travel costs and this will be estimated from
the number of visits to, for example, a GP or hospital doc-
tor (estimated from the healthcare utilization questionnaire)and the unit cost of making a return journey to each
type of healthcare provider (from the healthcare unit
cost questionnaire).
The cost of participant’s time will be estimated by ask-
ing them how long they spent travelling to, and attend-
ing, their last visit to each type of healthcare provider.
Participants will also be asked what activity they would
have been undertaking (for example, paid work, leisure,
housework) had they not attended the healthcare provider.
This information will be presented in natural units, for ex-
ample, hours, and also costed using standard economic
conventions [25-27]. These unit time costs, measured
in terms of their natural and monetary terms, will then
be combined with estimates of number of healthcare
contacts derived as outlined next.
NHS costs of other health services used
Use of secondary care services following the treatment
period will be collected using a case report form. This
form will record information on non-protocol outpatient
visits (protocol visits are those scheduled for the pur-
poses of data collection) and readmissions relating to
the use and consequences of drug treatment. Data on
the use of primary care services, such as prescription
medications, contacts with primary care practitioners,
for example, GPs and practice nurses, will be collected
via the healthcare utilization questionnaire completed at
the 12-week follow-up.
Cost-effectiveness
The cost-effectiveness within the trial will be measured
in terms of the number of participants needing further
treatment during or at the end of the 12-week follow-up
and the number of QALYs at 12 weeks. The number of
QALYs will be estimated by combining estimated quantity
of life, with quality of life derived from the EQ5D question-
naire (administered at baseline, 4 weeks and 12 weeks post
randomization) and UK tariffs [28].
The within-trial analysis will be based on the 12-week
follow-up and the results will be presented as the incre-
mental cost per further treatments needed during or at
the end of the 12-week follow-up and the incremental
cost per QALY gained. The results will be presented as
point estimates of mean incremental costs, number of
further treatments needed, QALYs, incremental cost
per further treatment needed and incremental cost per
QALY. Measures of variance for these outcomes are
likely to involve bootstrapping estimates of costs, num-
ber of further treatments needed, QALYs, incremental
cost per further treatments needed and incremental
cost per QALY. Incremental cost-effectiveness data will be
presented in terms of cost-effectiveness acceptability curves.
Forms of uncertainty, for example, concerning the unit cost
of a resource from the different centres, will be addressed
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results of the sensitivity analyses will also be presented as
cost-effectiveness acceptability curves.
A modelling exercise will be performed to extrapolate
the estimates of the cost-utility analysis to a longer time
horizon than that considered by the trial. This will allow
consideration of the costs of any subsequent treatments
performed after the trial follow-up period and effects on
quality of life prior to this. Consideration will also be
given to the relevance of costs and effects on quality of
life following subsequent treatment. Individual partici-
pant data from the trial as well as both published and
unpublished evidence in the field will be used to popu-
late the model. The methods used to assemble additional
data will follow recognized methodologies, which will
vary according to the type of parameter, extent of uncer-
tainty and role within the model. Therefore, comprehensive
systematic searching will be limited to those parameters
to which the results of the model are likely to be particu-
larly sensitive. The modelling exercise will comply with
recent recommendations on good practice for model-
ling; results will be presented in terms of incremental
cost per additional treatment needed and incremental
cost per QALY gained. Parameters and other forms of
uncertainty will be addressed using probabilistic and
deterministic sensitivity analysis.
Ethical approval
The East of Scotland Research Ethics Committee reviewed
and approved this study on 15 June 2010 (REC reference
number, 10/S0501/31). The trial is conducted in accordance
with the principles of Good Clinical Practice and complies
with the Declaration of Helsinki (2000).
Discussion
The main practical challenge of this trial has been the
identification and recruitment of participants, owing to
the nature of ureteric stone disease and the care pathway
for these patients within the NHS. The majority of patients
present to secondary care units via emergency depart-
ments, often out of normal hours, and this is problematic
for site research staff, as there is no way of predicting
how, where and when these patients might seek treat-
ment. The availability of the clinical trial pharmacist
(often only during normal office hours) to dispense
trial medication has also had implications for recruitment.
In some cases, participants have volunteered to come back
and collect trial medication during pharmacy hours, but
there have been occasions where they have not complied
with this requirement.
As the trial has progressed, we have seen a lower than
expected response rate to the participant questionnaires.
Strategies to improve response rate have been employed,
including text-message pre-notification of questionnairedelivery, email delivery of reminder questionnaires,
short- form questionnaires at 12 weeks (capturing the
EQ5D data only) and monetary incentives (unconditional
£5 gift voucher for UK high street stores) sent with the
12-week questionnaires. The impact of these will be
discussed in the full trial report.
Our choice of primary outcome measure, where stone
passage is defined as no further intervention required, is
a pragmatic one and encompasses patient (symptoms),
clinical (continued presence of stone), and healthcare
delivery aspects of stone treatment. Although previous
triallists have recorded stone-free rate as confirmed by
imaging techniques (for example, CTKUB, plain X-ray of
the kidney, ureter and bladder), we considered that
participants would not receive imaging as part of their
standard care in the NHS and that there are safety concerns
with asking them to undergo such procedures purely
to fulfil the requirements of the trial. Additionally,
stone-free rate confirmed by imaging does not allow
for a cost-effectiveness assessment, which will be key
to evaluating the effect of MET. Any possible centre and
other biases relating to outcome attribution and recording
should be mitigated by blinding of the participants and
healthcare professionals, randomization and the high
sample size of the trial.
Other than these problems, there have been no main
issues in conducting the SUSPEND trial. We advise
researchers considering studies in a similar setting to
consider carefully the practicalities of recruitment and
availability of research staff; both those involved in the
trial and those in supporting services (for example, the
clinical trial pharmacy).
Trial status
The first participant was recruited in January 2011 and the
trial is currently open to recruitment in 25 UK centres.
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